Get the Stockscreener App
90.65
1.60%
1.43
Pre-market:
89.90
-0.75
-0.83%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $90.65, with a volume of 5.95M.
It is up +1.60% in the last 24 hours and up +7.34% over the past month.
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$89.22
Open:
$89.86
24h Volume:
5.95M
Relative Volume:
0.72
Market Cap:
$402.40B
Revenue:
$42.09B
Net Income/Loss:
$14.65B
P/E Ratio:
27.61
EPS:
3.2833
Net Cash Flow:
$10.11B
1W Performance:
+2.92%
1M Performance:
+7.34%
6M Performance:
-34.86%
1Y Performance:
-24.31%
1-Day Range:
$89.38
$90.72
1-Week Range:
$88.12
$93.80
52-Week Range:
$77.82
$148.15
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
90.65 | 402.40B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
LLY
Lilly Eli Co
|
920.63 | 874.97B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
209.03 | 369.01B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
165.02 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
92.25 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
Where Will Eli Lilly Be in 5 Years? - The Motley Fool
Are Investors Inclined To Sell Their Novo Nordisk ADR (NYSE: NVO) Holdings? - Stocks Register
The Attractiveness of Investing In Novo Nordisk ADR (NVO) is Growing - Knox Daily
Ero Copper Corp (ERO) gets rating Initiated from Goldman - Knox Daily
Itau Unibanco Holding S.A. ADR (ITUB) Stock Records -5.92% Quarterly Movement - The News Heater
Novo Nordisk ADR (NVO) Shares Decline Despite Market Challenges - The News Heater
A Stock Analysis Of Novo Nordisk ADR’s (NVO) - Stocks Register
Examining Novo Nordisk ADR (NVO) more closely is necessary - US Post News
NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up - MSN
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth - Morningstar
Novo Nordisk ADR [NVO] Is Currently -0.04 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Novo Nordisk Stock Rises After Earnings. It Expects Good News From the FDA. - Barron's
Novo Nordisk Shares Surge on Strong Sales of Wegovy, Despite Slight Earnings Miss – market - HPBL
Novo Nordisk Stock Up After Earnings. Weight-Loss Drugmaker Sees Slower Growth. - Barron's
Novo Nordisk ADR earnings beat by $5.46, revenue topped estimates - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/SNVO - cnhinews.com
Novo Nordisk ADR (NVO) Stock: A Look at the Analyst Recommendations - The News Heater
Novo Nordisk: Next-Generation GLP-1/Amylin Drug Sees Leading Weight Loss in Small Trial - Morningstar
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):